Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00006942 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

NIH

Sponsor class

Conditions

Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions

DRUG: bryostatin 1
DRUG: cisplatin
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)